GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » Total Receivables

Fractyl Health (Fractyl Health) Total Receivables : $0.02 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health Total Receivables?

Fractyl Health's Total Receivables for the quarter that ended in Mar. 2024 was $0.02 Mil.


Fractyl Health Total Receivables Historical Data

The historical data trend for Fractyl Health's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health Total Receivables Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
- - - - 0.02

Fractyl Health Quarterly Data
Dec19 Jun20 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.06 0.02 0.02 0.02

Fractyl Health Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Fractyl Health Total Receivables Related Terms

Thank you for viewing the detailed overview of Fractyl Health's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Fractyl Health (Fractyl Health) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hartwell Avenue, Lexington, MA, USA, 02421
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity.